Comparative Study of 250 Mg/day Terbinafine and 100 Mg/day Itraconazole for the Treatment of Cutaneous Sporotrichosis

Overview

Journal Mycopathologia

Specialties Microbiology
Pharmacology

Date 2010 Nov 25

PMID 21103938

Citations 24

Authors

Glaucia Francesconi

Antonio Carlos Francesconi do Valle

Sonia Lambert Passos

Monica Bastos de Lima Barros

Rodrigo de Almeida Paes

Andre Luiz Land Curi

Jose Liporage

Cassio Ferreira Porto

Maria Clara Gutierrez Galhardo

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Itraconazole is currently used for the treatment of cutaneous sporotrichosis. Terbinafine at a daily dose of 250 mg has been successfully applied to the treatment of cutaneous sporotrichosis.

Objective: To compare the efficacy of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis.

Materials And Methods: A bidirectional cohort study was conducted on 55 patients receiving 250 mg/day terbinafine and 249 patients receiving 100 mg/day itraconazole. The latter patients were matched for age and clinical form to the terbinafine group at a ratio of 5:1. Sporothrix schenckii was isolated by culture from all patients (age range: 18-70 years), who were submitted to the standard care protocol consisting of clinical and laboratory evaluation and periodic visits.

Results: Cure was observed in 51 (92.7%) patients of the terbinafine group and 229 (92%) of the itraconazole group within a similar mean period of time (11.5 and 11.8 weeks, respectively). An increase in the terbinafine dose to 500 mg was necessary in two patients due to the lack of a response, and one patient presented recurrence. In the itraconazole group, two patients required a dose increase and three presented recurrence. Adverse events were equally frequent among patients receiving terbinafine (n = 4, 7.3%) and itraconazole (n = 19, 7.6%) and were generally mild without the need for drug discontinuation, except for two patients of the itraconazole group.

Conclusion: Terbinafine administered at a daily dose of 250 mg is an effective and well-tolerated option for the treatment of cutaneous sporotrichosis.

Citing Articles

Sporotrichosis caused by in an elderly male farmer at the site of a cat scratch.

Sakai Y, Norimatsu Y, Akatsuka T, Hamada T, Gomi H, Sugaya M Med Mycol Case Rep. 2024; 46:100667.

PMID: 39314641 PMC: 11416248. DOI: 10.1016/j.mmcr.2024.100667.

Invasive fungal infections and oomycoses in cats 2. Antifungal therapy.

Barrs V, Hobi S, Wong A, Sandy J, Shubitz L, Beczkowski P J Feline Med Surg. 2024; 26(1):1098612X231220047.

PMID: 38189264 PMC: 10949877. DOI: 10.1177/1098612X231220047.

Whole transcriptome sequencing for revealing the pathogenesis of sporotrichosis caused by Sporothrix globosa.

Liu Z, Li S, Zhang G, Lv S, Wang S, Li F Sci Rep. 2024; 14(1):359.

PMID: 38172590 PMC: 10764346. DOI: 10.1038/s41598-023-50728-7.

Endemic mycoses - are we making progress in management?.

Bahr N, Thompson 3rd G Curr Opin Infect Dis. 2023; 36(6):436-442.

PMID: 37755392 PMC: 10840811. DOI: 10.1097/QCO.0000000000000971.

Chieosilapatham P, Chuamanochan M, Chiewchavit S, Saikruatep R, Amornrungsun E, Preechasuth K Med Mycol Case Rep. 2023; 41:44-47.

PMID: 37706041 PMC: 10495378. DOI: 10.1016/j.mmcr.2023.08.003.

References

Song Y, Zhong S, Yao L, Cai Q, Zhou J, Liu Y . Efficacy and safety of itraconazole pulses vs. continuous regimen in cutaneous sporotrichosis. J Eur Acad Dermatol Venereol. 2010; 25(3):302-5. DOI: 10.1111/j.1468-3083.2010.03785.x. View

Faergemann J, Zehender H, Jones T, Maibach I . Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. Acta Derm Venereol. 1991; 71(4):322-6. View

Galhardo M, De Oliveira R, do Valle A, Paes R, Silvatavares P, Monzon A . Molecular epidemiology and antifungal susceptibility patterns of Sporothrix schenckii isolates from a cat-transmitted epidemic of sporotrichosis in Rio de Janeiro, Brazil. Med Mycol. 2008; 46(2):141-51. DOI: 10.1080/13693780701742399. View

Kusuhara M, Hachisuka H, Sasai Y . Statistical survey of 150 cases with sporotrichosis. Mycopathologia. 1988; 102(2):129-33. DOI: 10.1007/BF00437450. View

Tanuma H, Asai T, Abe M, Nishiyama S, Katsuoka K . Case report. Lymphatic vessel-type sporotrichosis: immunohistochemical evaluation and cytokine expression pattern. Mycoses. 2001; 44(7-8):316-20. View

Hay R . Therapeutic potential of terbinafine in subcutaneous and systemic mycoses. Br J Dermatol. 2000; 141 Suppl 56:36-40. DOI: 10.1046/j.1365-2133.1999.00013.x. View

Trilles L, Fernandez-Torres B, Lazera M, Wanke B, Schubach A, Paes R . In vitro antifungal susceptibilities of Sporothrix schenckii in two growth phases. Antimicrob Agents Chemother. 2005; 49(9):3952-4. PMC: 1195444. DOI: 10.1128/AAC.49.9.3952-3954.2005. View

Marimon R, Serena C, Gene J, Cano J, Guarro J . In vitro antifungal susceptibilities of five species of sporothrix. Antimicrob Agents Chemother. 2007; 52(2):732-4. PMC: 2224726. DOI: 10.1128/AAC.01012-07. View

Kauffman C, Bustamante B, Chapman S, Pappas P . Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007; 45(10):1255-65. DOI: 10.1086/522765. View

10.

Vickers A, Sinclair J, ZOLLINGER M, Heitz F, Glanzel U, Johanson L . Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos. 1999; 27(9):1029-38. View

11.

Hull P, Vismer H . Treatment of cutaneous sporotrichosis with terbinafine. Br J Dermatol. 1992; 126 Suppl 39:51-5. DOI: 10.1111/j.1365-2133.1992.tb00011.x. View

12.

CONTI DIAZ I, Civila E, Gezuele E, Lowinger M, Calegari L, Sanabria D . Treatment of human cutaneous sporotrichosis with itraconazole. Mycoses. 1992; 35(5-6):153-6. DOI: 10.1111/j.1439-0507.1992.tb00836.x. View

13.

Pappas P, Tellez I, Deep A, Nolasco D, Holgado W, Bustamante B . Sporotrichosis in Peru: description of an area of hyperendemicity. Clin Infect Dis. 2000; 30(1):65-70. DOI: 10.1086/313607. View

14.

Restrepo A, Robledo J, Gomez I, Tabares A, Gutierrez R . Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. Arch Dermatol. 1986; 122(4):413-7. View

15.

Barros M, Schubach A, do Valle A, Galhardo M, Conceicao-Silva F, Schubach T . Cat-transmitted sporotrichosis epidemic in Rio de Janeiro, Brazil: description of a series of cases. Clin Infect Dis. 2004; 38(4):529-35. DOI: 10.1086/381200. View

16.

Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239-45. DOI: 10.1038/clpt.1981.154. View

17.

Noguchi H, Hiruma M, Kawada A . Case report. Sporotrichosis successfully treated with itraconazole in Japan. Mycoses. 1999; 42(9-10):571-6. DOI: 10.1046/j.1439-0507.1999.00484.x. View

18.

Coskun B, Saral Y, Akpolat N, Ataseven A, Cicek D . Sporotrichosis successfully treated with terbinafine and potassium iodide: case report and review of the literature. Mycopathologia. 2004; 158(1):53-6. DOI: 10.1023/b:myco.0000038440.18814.a9. View

19.

Marimon R, Cano J, Gene J, Sutton D, Kawasaki M, Guarro J . Sporothrix brasiliensis, S. globosa, and S. mexicana, three new Sporothrix species of clinical interest. J Clin Microbiol. 2007; 45(10):3198-206. PMC: 2045377. DOI: 10.1128/JCM.00808-07. View

20.

CONTI DIAZ I . Epidemiology of sporotrichosis in Latin America. Mycopathologia. 1989; 108(2):113-6. DOI: 10.1007/BF00436061. View